2-(2-methanesulfonylethyl)pyridine | 298181-79-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-(2-methanesulfonylethyl)pyridine
• 英文别名: 2-(2-Methanesulfonyl-ethyl)-pyridine；2-(2-methylsulfonylethyl)pyridine
• CAS: 298181-79-0
• 化学式: C₈H₁₁NO₂S
• 分子量: 185.247
• InChiKey: ZHKDQKYDJUYJJY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  55.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-(2-nitrobenzenesulfonyl)-N-(2-pyridinylmethyl)-N'-(5,6,7,8-tetrahydro-8-quinolinyl)-1,4-benzenedimethanamine 、 2-(2-methanesulfonylethyl)pyridine 在 potassium iodide 作用下， 以 乙腈 为溶剂， 以100%的产率得到2-nitro-N-(4-(((2-(pyridin-2-yl)ethyl)(5,6,7,8-tetrahydroquinolin-8-yl)amino)methyl)benzyl)-N-(pyridin-2-ylmethyl)benzenesulfonamide
  参考文献：
  名称：

  Discovery of Novel Small Molecule Orally Bioavailable C−X−C Chemokine Receptor 4 Antagonists That Are Potent Inhibitors of T-Tropic (X4) HIV-1 Replication

  摘要：

  The redesign of azamacrocyclic CXCR4 chemokine receptor antagonists resulted in the discovery of novel, small molecule, orally bioavailable compounds that retained T-tropic (CXCR4 using, X4) anti-HIV-1 activity. A structure activity relationship (SA R) was determined on the basis of the inhibition of replication of X4 HIV-1 NL4.3 in MT-4 cells. As a result of lead optimization, we identified (S)-N'-((1H-benzo[d]imidazol-2-Amethyl)-N'-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine (AMD070) 2 as a potent and selective antagonist of CXCR4 with an IC(50) value of 13 nM in a CXCR4 (125)I-SDF inhibition binding assay. Compound 2 inhibited the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs with an IC(50) of 2 and 26 nM, respectively, while remaining noncytotoxic to cells at concentrations exceeding 23 mu M. The pharmacokinetics of 2 was evaluated in rat and dog, and good oral bioavailability was observed in both species. This compound represents the first small molecule orally bioavailable CXCR4 antagonist that was developed for the treatment of HIV-1 infection.

  DOI：

  10.1021/jm100073m
• 作为产物：
  描述：

  2-乙烯基吡啶 、 sodium methansulfinate 在 溶剂黄146 作用下， 以 乙醇 为溶剂， 反应 20.0h， 以91%的产率得到2-(2-methanesulfonylethyl)pyridine
  参考文献：
  名称：

  将甲磺酸钠共轭添加到乙烯基吡啶和二嗪中以合成脂肪族砜

  摘要：

  描述了将砜基引入吡啶和二嗪的简便方法。这种有效的方法涉及将亚磺酸钠共轭加成到乙烯基杂环上。该方法可耐受多种官能团，并且在乙酸或三氟乙酸的存在下进行。还描述了从相应的杂芳基卤化物开始的一锅，两步合成砜。

  DOI：

  10.1016/j.tetlet.2009.02.037

文献信息

• [EN] NOVEL POTASSIUM CHANNEL BLOCKERS AND USES THEREOF<br/>[FR] NOUVEAUX BLOQUEURS DU CANAL POTASSIQUE ET LEURS UTILISATIONS
  申请人：BIONOMICS LTD

  公开号：WO2009149508A1

  公开（公告）日：2009-12-17

  The present invention relates to compounds useful in the modulation of potassium channel activity in cells, in particular the activity of Kv1.3 channels found in T cells. The invention also relates to the use of these compounds in the treatment or prevention of autoimmune and inflammatory diseases, including multiple sclerosis, pharmaceutical compositions containing these compounds and methods for their preparation.

  本发明涉及一种在细胞中调节钾通道活性的化合物，特别是用于T细胞中发现的Kv1.3通道的活性。该发明还涉及利用这些化合物治疗或预防自身免疫和炎症性疾病，包括多发性硬化症，含有这些化合物的药物组合物以及其制备方法。
• [EN] N-SUBSTITUTED BENZENE SULFONAMIDES<br/>[FR] BENZENESULFONAMIDES N-SUBSTITUES
  申请人：ELAN PHARM INC

  公开号：WO2005042489A1

  公开（公告）日：2005-05-12

  Disclosed are N-substituted benzenesulfonamides for use intreating in treating or preventing cognitive disorders, such as Alzheimer´s Disease. Formula (I) In formula (I), R1, R2, R3, R4, R3’, R10 and R11 are described herein. The invention also encompasses pharmaceutical compositions comprising compounds of Formula(I) as well as methods of treating cognitive using compounds of Formula (I).

  揭示了用于治疗或预防认知障碍，如阿尔茨海默病的N-取代苯磺酰胺。公式（I）在公式（I）中，R1、R2、R3、R4、R3'、R10和R11如本文所述。本发明还涵盖了包括公式（I）化合物的药物组合物，以及使用公式（I）化合物治疗认知障碍的方法。
• Chemokine receptor binding heterocyclic compounds
  申请人：——

  公开号：US20040235823A1

  公开（公告）日：2004-11-25

  This invention relates to a novel class of heterocyclic compounds that bind chemokine receptors, inhibiting the binding of their natural ligands thereby. These compounds result in protective effects against infection by HIV through binding to chemokine receptors, including CXCR4 and CCR5, thus inhibiting the subsequent binding by these chemokines. The present invention provides a compound of Formula I 1 wherein, W is a nitrogen atom and Y is absent or, W is a carbon atom and Y=H; R 1 to R 7 may be the same or different and are independently selected from hydrogen or straight, branched or cyclic C 1-6 alkyl; R 8 is a substituted heterocyclic group or a substituted aromatic group Ar is an aromatic or heteroaromatic ring each optionally substituted at single or multiple, non-linking positions with electron-donating or withdrawing groups; n and n′ are independently, 0-2; X is a group of the formula: 2 Wherein, Ring A is an optionally substituted, saturated or unsaturated 5 or 6-membered ring, and P is an optionally substituted carbon atom, an optionally substituted nitrogen atom, sulfur or oxygen atom. Ring B is an optionally substituted 5 to 7-membered ring. Ring A and Ring B in the above formula can be connected to the group W from any position via the group V, wherein V is a chemical bond, a (CH 2 ) n″ group (where n″=0-2) or a C═O group. Z is, (1) a hydrogen atom, (2) an optionally substituted C 1-6 alkyl group, (3) a C 0-6 alkyl group substituted with an optionally substituted aromatic or heterocyclic group, (4) an optionally substituted C 0-6 alkylamino or C 3-7 cycloalkylamino group, (5) an optionally substituted carbonyl group or sulfonyl. These compounds further include any pharmaceutically acceptable acid addition salts and metal complexes thereof and any stereoisomeric forms and mixtures of stereoisomeric forms thereof.

  本发明涉及一类新型杂环化合物，其能够结合趋化因子受体，抑制其自然配体的结合。这些化合物通过结合趋化因子受体，包括CXCR4和CCR5，从而抑制这些趋化因子的后续结合，从而产生对HIV感染的保护作用。本发明提供了一种I1式化合物，其中，W是氮原子，Y不存在或W是碳原子且Y=H；R1至R7可以相同也可以不同，且独立地选择氢或直链、支链或环状C1-6烷基；R8是取代的杂环基或取代的芳香基；Ar是芳香或杂芳环，可以在单个或多个非连接位置上选择电子给体或电子受体基团进行取代；n和n'独立地为0-2；X是以下式的基团：式中，环A是可选择取代的饱和或不饱和5或6元环，P是可选择取代的碳原子、可选择取代的氮原子、硫或氧原子。环B是可选择取代的5至7元环。上述式中的环A和环B可以通过基团V从任何位置连接到基团W，其中V是化学键、(CH2)n''基团(n''=0-2)或C═O基团。Z是(1)氢原子，(2)可选择取代的C1-6烷基，(3)取代的C0-6烷基，取代的芳香或杂环基，(4)可选择取代的C0-6烷基氨基或C3-7环烷基氨基基团，(5)可选择取代的羰基或磺酰基。这些化合物还包括任何药学上可接受的酸加成盐和金属配合物以及其任何立体异构体和立体异构体混合物。
• N-substituted benzene sulfonamides
  申请人：Neitzel Martin

  公开号：US20050165003A1

  公开（公告）日：2005-07-28

  Disclosed are N-substituted benzenesulfonamides for use in treating or preventing cognitive disorders, such as Alzheimer's Disease. In Formula (I), R 1 , R 2 , R 3 , R 4 , R 3′ , R 10 and R 11 are as described herein. The invention also encompasses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of treating cognitive disorders using compounds of Formula (I).

  本发明涉及用于治疗或预防认知障碍（例如阿尔茨海默病）的N-取代苯磺酰胺。在式（I）中，R1、R2、R3、R4、R3′、R10和R11如所述。本发明还包括包含式（I）化合物的药物组合物，以及使用式（I）化合物治疗认知障碍的方法。
• Alpha ketoamide compounds as cysteine protease inhibitors
  申请人：Graupe Michael

  公开号：US20070021353A1

  公开（公告）日：2007-01-25

  The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.

  本发明涉及一种抑制半胱氨酸蛋白酶的化合物，特别是对卡特普西蛋白B、K、L、F和S的抑制剂，因此可以用于治疗由这些蛋白酶介导的疾病。本发明涉及包含这些化合物的制药组合物和制备它们的方法。